13 research outputs found
The Interspersed Spin Boson Lattice Model
We describe a family of lattice models that support a new class of quantum
magnetism characterized by correlated spin and bosonic ordering [Phys. Rev.
Lett. 112, 180405 (2014)]. We explore the full phase diagram of the model using
Matrix-Product-State methods. Guided by these numerical results, we describe a
modified variational ansatz to improve our analytic description of the
groundstate at low boson frequencies. Additionally, we introduce an
experimental protocol capable of inferring the low-energy excitations of the
system by means of Fano scattering spectroscopy. Finally, we discuss the
implementation and characterization of this model with current circuit-QED
technology.Comment: Submitted to EPJ ST issue on "Novel Quantum Phases and Mesoscopic
Physics in Quantum Gases
Digital Quantum Simulation with Rydberg Atoms
We discuss in detail the implementation of an open-system quantum simulator
with Rydberg states of neutral atoms held in an optical lattice. Our scheme
allows one to realize both coherent as well as dissipative dynamics of complex
spin models involving many-body interactions and constraints. The central
building block of the simulation scheme is constituted by a mesoscopic Rydberg
gate that permits the entanglement of several atoms in an efficient, robust and
quick protocol. In addition, optical pumping on ancillary atoms provides the
dissipative ingredient for engineering the coupling between the system and a
tailored environment. As an illustration, we discuss how the simulator enables
the simulation of coherent evolution of quantum spin models such as the
two-dimensional Heisenberg model and Kitaev's toric code, which involves
four-body spin interactions. We moreover show that in principle also the
simulation of lattice fermions can be achieved. As an example for controlled
dissipative dynamics, we discuss ground state cooling of frustration-free spin
Hamiltonians.Comment: submitted to special issue "Quantum Information with Neutral
Particles" of "Quantum Information Processing
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey
Altres ajuts: British Society for Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT); UK NIHR Imperial College Biomedical Research Centre.This study reports on 382 COVID-19 patients having undergone allogeneic (n = 236) or autologous (n = 146) hematopoietic cell transplantation (HCT) reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). The median age was 54.1 years (1.0-80.3) for allogeneic, and 60.6 years (7.7-81.6) for autologous HCT patients. The median time from HCT to COVID-19 was 15.8 months (0.2-292.7) in allogeneic and 24.6 months (−0.9 to 350.3) in autologous recipients. 83.5% developed lower respiratory tract disease and 22.5% were admitted to an ICU. Overall survival at 6 weeks from diagnosis was 77.9% and 72.1% in allogeneic and autologous recipients, respectively. Children had a survival of 93.4%. In multivariate analysis, older age (p = 0.02), need for ICU (p < 0.0001) and moderate/high immunodeficiency index (p = 0.04) increased the risk while better performance status (p = 0.001) decreased the risk for mortality. Other factors such as underlying diagnosis, time from HCT, GVHD, or ongoing immunosuppression did not significantly impact overall survival. We conclude that HCT patients are at high risk of developing LRTD, require admission to ICU, and have increased mortality in COVID-19
Outcome of Cytogenetics in Patients with Newly Diagnosed Extramedullary Myeloma Undergoing Stem-Cell Transplantation
IF 9.090 (2017)International audienc
Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT
We performed a registry study on therapy-related myeloid neoplasm (t-MN), both therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) following treatment for breast cancer who underwent a first allogeneic hematopoietic cell transplant (allo-HCT). Of 252 identified female patients (median age 57 years), 77% were transplanted for t-AML and 23% for t-MDS, with a median time from breast cancer diagnosis to the diagnosis of tMN and subsequent allo-HCT of 3.7 and 4.6 years, respectively. At transplant, 191 patients were in remission for breast cancer, while 4 were not (57 missing). T-MN was in a complete remission at the time of transplant in 67% of patients. 2-year overall survival, relapse free-survival, relapse incidence and non-relapse mortality were 50%, 45%, 33%, and 22%, respectively. Multivariable analysis revealed that if the t-MN was not in CR pre-transplant, this was associated with lower OS, RFS, and a higher relapse incidence. Seventeen cases of breast cancer recurrence were recorded after a median of 2.4 years post-transplant, and relapse of primary breast cancer accounted for 7% of deaths. This study indicates that allo-HCT for t-MN following treatment for breast cancer shows encouraging transplant outcomes. The incidence of breast cancer relapse post-transplant remains a cause for concern
Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT
We performed a registry study on therapy-related myeloid neoplasm (t-MN), both therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) following treatment for breast cancer who underwent a first allogeneic hematopoietic cell transplant (allo-HCT). Of 252 identified female patients (median age 57 years), 77% were transplanted for t-AML and 23% for t-MDS, with a median time from breast cancer diagnosis to the diagnosis of tMN and subsequent allo-HCT of 3.7 and 4.6 years, respectively. At transplant, 191 patients were in remission for breast cancer, while 4 were not (57 missing). T-MN was in a complete remission at the time of transplant in 67% of patients. 2-year overall survival, relapse free-survival, relapse incidence and non-relapse mortality were 50%, 45%, 33%, and 22%, respectively. Multivariable analysis revealed that if the t-MN was not in CR pre-transplant, this was associated with lower OS, RFS, and a higher relapse incidence. Seventeen cases of breast cancer recurrence were recorded after a median of 2.4 years post-transplant, and relapse of primary breast cancer accounted for 7% of deaths. This study indicates that allo-HCT for t-MN following treatment for breast cancer shows encouraging transplant outcomes. The incidence of breast cancer relapse post-transplant remains a cause for concern.Immunobiology of allogeneic stem cell transplantation and immunotherapy of hematological disease